EUVIMEDEUVIMED entdecken
Crossref

Development, optimization, and scale‐up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus‐1

Chun Fang Shen iD, Elodie Burney, Rénald Gilbert, S Mehdy Elahi, Kelley Parato, Martin Loignon

Biotechnology Journal · 2024-01 · 19 (1)

DOI: 10.1002/biot.202300244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, online erschienen am 15.10.2023. Verfasst von Chun Fang Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, Canada. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Oncolytic Viruses. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, and four OVs have been approved for cancer immunotherapy. However, high‐yield and cost‐effective production processes remain to be developed for most OVs. Here suspension‐adapted Vero cell culture processes were developed for high titer production of an OV model, herpes simplex virus type 1 (HSV‐1). Our study showed the HSV‐1 productivity was significantly affected by multiplicity of infection, cell density, and nutritional supplies. Cell culture conditions were first optimized in shake flask experiments and then scaled up to 3 L bioreactors for virus production under batch and perfusion modes. A titer of 2.7 × 10 8 TCID50 mL −1 was obtained in 3 L batch culture infected at a cell density of 1.4 × 10 6 cells mL −1 , and was further improved to 1.1 × 10 9 TCID50 mL −1 in perfusion culture infected at 4.6 × 10 6 cells mL −1 . These titers are similar to or better than the previously reported best titer of 8.6 × 10 7 TCID50 mL −1 and 8.1 × 10 8 TCID50 mL −1 respectively obtained in labor‐intensive adherent Vero batch and perfusion cultures. HSV‐1 production in batch culture was successfully scaled up to 60 L pilot‐scale bioreactor to demonstrate the scalability. The work reported here is the first study demonstrating high titer production of HSV‐1 in suspension Vero cell culture under different bioreactor operating modes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 1, HumanOncolytic VirusesAnimalsChlorocebus aethiopsVero CellsBatch Cell Culture TechniquesBioreactorsVirus Cultivation

Stichwörter der Autor:innen

herpes simplex virusoncolytic virusesperfusion culturesuspension Vero cell

Autor:innen und Institutionen

  • Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, Canada.

ORCID-Profile: Chun Fang Shen

Zitieren

APA

Shen, C. F., Burney, E., Gilbert, R., Elahi, S. M., Parato, K., & Loignon, M. (2024). Development, optimization, and scale‐up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus‐1. Biotechnology Journal, 19(1). https://doi.org/10.1002/biot.202300244

Vancouver

Shen CF, Burney E, Gilbert R, Elahi SM, Parato K, Loignon M. Development, optimization, and scale‐up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus‐1. Biotechnology Journal. 2024;19(1). doi:10.1002/biot.202300244

BibTeX
@article{Shen2024,
  author = {Shen, Chun Fang and Burney, Elodie and Gilbert, Rénald and Elahi, S Mehdy and Parato, Kelley and Loignon, Martin},
  title = {Development, optimization, and scale‐up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus‐1},
  journal = {Biotechnology Journal},
  year = {2024},
  volume = {19},
  number = {1},
  doi = {10.1002/biot.202300244}
}
Kostenlos starten →